Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Autoimmune pulmonary alveolar
proteinosis (aPAP) is a syndrome characterised by the accumulation of lipids
and proteins related to surfactants in the alveoli in association with
antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). The
disease causes progressive impairment of gas exchange and respiratory
insufficiency. This blocks air from entering alveoli and oxygen from passing
through into the blood, resulting in breathlessness. Most patients develop
dyspnea very slowly over time, typically noticing it only with activity at
first and eventually at rest. As the disease gets worse from the build-up of
surfactant, the fingertips can become bluish in colour due to a low level of
oxygen in the blood. Cough is the following most common symptom. This can be a
dry or productive cough that produces whitish phlegm. Coughing phlegm with
streaks of blood, with or without fever, usually indicates that infection is
also present.
- The prevalence of Autoimmune pulmonary alveolar proteinosis
ranges from 15 to 20 cases per million population in the USA.
Thelansis’s “Autoimmune Pulmonary
Alveolar Proteinosis (aPAP) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Autoimmune
Pulmonary Alveolar Proteinosis (aPAP) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) across 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Autoimmune Pulmonary Alveolar
Proteinosis (aPAP) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment